# Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

> **NCT02564263** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 628 (actual)

## Conditions studied

- Esophageal Carcinoma
- Esophagogastric Junction Carcinoma

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **DRUG:** paclitaxel
- **DRUG:** docetaxel
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT02564263
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-01
- **Primary completion:** 2018-10-15
- **Final completion:** 2022-03-14
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564263, "Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02564263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*